DC
Carballo, David Andrés
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes | Atherosclerosis plus |  | 2024 | 7 | 8 | ||
| Drinking patterns of alcohol and risk of major adverse cardiovascular events after an acute coronary syndrome | European journal of preventive cardiology | | 2024 | 60 | 92 | ||
| Case report : desmoplakin cardiomyopathy presenting as an inflammatory cardiomyopathy with repeated sudden cardiac arrests | European heart journal. Case reports | | 2024 | 11 | 49 | ||
| Effects of SARS-COV-2 infection on outcomes in patients hospitalized for acute cardiac conditions. A prospective, multicenter cohort study (Swiss Cardiovascular SARS-CoV-2 Consortium) | Frontiers in cardiovascular medicine | | 2023 | 95 | 23 | ||
| Initial systolic blood pressure associates with systemic inflammation, myocardial injury, and outcomes in patients with acute coronary syndromes | European heart journal. Acute cardiovascular care | | 2023 | 57 | 142 | ||
| Utilité clinique des genome boards pour les maladies génétiques complexes | Revue médicale suisse | | 2023 | 179 | 96 | ||
| Utilisation de l’acétazolamide dans l’insuffisance cardiaque aiguë | Revue médicale suisse | | 2023 | 88 | 83 | ||
| Recommandations européennes 2021 pour la prévention cardiovasculaire : nouveautés | Revue médicale suisse |  | 2022 | 288 | 2 | ||
| Long-term effects of systematic smoking cessation counselling during acute coronary syndrome, a multicentre before-after study | Swiss medical weekly | | 2022 | 72 | 45 | ||
| Effectiveness, adherence, and safety of evolocumab in a swiss multicenter prospective observational study | Advances in therapy | | 2022 | 221 | 200 | ||
| The 'ten commandments' for the 2021 ESC Guidelines on CVD prevention | European heart journal | | 2022 | 122 | 227 | ||
| European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology | European journal of preventive cardiology | | 2022 | 259 | 0 | ||
| Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute heart failure: a retrospective, non-inferiority, cohort study | BMJ open | | 2022 | 128 | 67 | ||
| 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice | European journal of preventive cardiology | | 2022 | 420 | 2,126 | ||
| Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS)-A phase II, randomized, double-blind, multi-center, placebo-controlled trial | The American heart journal | | 2022 | 162 | 0 | ||
| Prognosis of Laboratory-Confirmed Influenza and Respiratory Syncytial Virus in Acute Heart Failure | Journal of clinical medicine | | 2021 | 230 | 87 | ||
| Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease | Open Heart | | 2021 | 247 | 165 | ||
| Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events | Atherosclerosis | | 2021 | 223 | 56 | ||
| Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) 2.0 Risk Score in Patients With Acute Coronary Syndromes | Journal of the American Heart Association | | 2021 | 208 | 122 | ||
| 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice | European heart journal | | 2021 | 648 | 9 | ||
| The value of cohort studies in cardiovascular medicine |  | 2021 | 406 | 0 | |||
| CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients | Atherosclerosis | | 2021 | 167 | 51 | ||
| Changement climatique et enjeux cliniques | Revue médicale suisse | | 2021 | 227 | 4 | ||
| Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode | Swiss medical weekly | | 2021 | 288 | 115 | ||
| Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines | European journal of preventive cardiology | | 2021 | 163 | 0 | ||
| Optimal timing of invasive coronary angiography following NSTEMI | Journal of interventional cardiology | | 2020 | 237 | 122 | ||
| Prognosis of patients eligible for dapagliflozin in acute heart failure | European journal of clinical investigation | | 2020 | 227 | 0 | ||
| Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort | International journal of cardiology | | 2020 | 221 | 0 | ||
| Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors | International journal of cardiology | | 2020 | 160 | 0 | ||
| Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure | ESC heart failure | | 2020 | 275 | 102 | ||
| La myocardite en 2020 | Revue médicale suisse | | 2020 | 467 | 656 | ||
| Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention | PloS one | | 2019 | 57 | 82 | ||
| Prognostic value of the echocardiographic probability of pulmonary hypertension in patients with acute decompensated heart failure | Journal of clinical medicine | | 2019 | 399 | 73 | ||
| Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease | International Journal of Molecular Sciences | | 2018 | 612 | 238 | ||
| Usefulness of P-wave signal averaging to predict atrial fibrillation recurrences after electrical cardioversion | Annals of noninvasive electrocardiology | | 2014 | 571 | 0 | ||
| A Palpable Source of Stroke | Circulation | | 2011 | 74 | 0 |
